MX388191B - Polinucleótido optimizado por codones para la expresión de alto nivel de crm197. - Google Patents

Polinucleótido optimizado por codones para la expresión de alto nivel de crm197.

Info

Publication number
MX388191B
MX388191B MX2017006506A MX2017006506A MX388191B MX 388191 B MX388191 B MX 388191B MX 2017006506 A MX2017006506 A MX 2017006506A MX 2017006506 A MX2017006506 A MX 2017006506A MX 388191 B MX388191 B MX 388191B
Authority
MX
Mexico
Prior art keywords
level expression
crm197
polynucleotide
codon
optimized polynucleotide
Prior art date
Application number
MX2017006506A
Other languages
English (en)
Other versions
MX2017006506A (es
Inventor
Akshay Goel
Mahima Datla
Narender Dev Mantena
Ravi Pratap Narayan Mishra
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of MX2017006506A publication Critical patent/MX2017006506A/es
Publication of MX388191B publication Critical patent/MX388191B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)

Abstract

La presente invención se relaciona a la expresión de alto nivel de toxoide bacteriano o proteína toxina de interés farmacológico por medio de una novedosa secuencia optimizada de polinucleótidos y un hospedero transformado con dicho polinucleótido. Específicamente, la invención proporciona un método para una alta producción de polipéptido CMR197 donde, el polinucleótido de la invención se usa para transformar un hospedero apropiado que resulta en la sobre-expresión de proteínas correspondientes y un método para aislar el polipéptido expresado. Más particularmente, la presente invención se relaciona a la expresión de alto nivel de CRM197 en Escherichia coli y un método para el aislamiento y purificación del mismo.
MX2017006506A 2014-11-20 2015-11-17 Polinucleótido optimizado por codones para la expresión de alto nivel de crm197. MX388191B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4045CH2014 2014-11-20
PCT/IN2015/000427 WO2016079755A1 (en) 2014-11-20 2015-11-17 Codon optimized polynucleotide for high level expression of crm197

Publications (2)

Publication Number Publication Date
MX2017006506A MX2017006506A (es) 2018-03-12
MX388191B true MX388191B (es) 2025-03-19

Family

ID=55346156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006506A MX388191B (es) 2014-11-20 2015-11-17 Polinucleótido optimizado por codones para la expresión de alto nivel de crm197.

Country Status (11)

Country Link
US (1) US10280409B2 (es)
EP (1) EP3221339B1 (es)
JP (2) JP2017538444A (es)
CN (1) CN107109416A (es)
AU (1) AU2015348922B2 (es)
CA (1) CA2968491C (es)
EA (1) EA035117B1 (es)
MX (1) MX388191B (es)
SA (1) SA517381488B1 (es)
WO (1) WO2016079755A1 (es)
ZA (1) ZA201703150B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3313436T (lt) 2015-06-23 2021-06-10 Biological E Limited Daugiavalentė pneumokokinė konjuguota vakcina
CU24660B1 (es) 2016-09-30 2023-05-11 Biological E Ltd Composiciones de vacunas multivalentes que comprenden conjugados de polisacárido-proteína de streptococcus pneumoniae utilizando proteínas portadoras psaa y crm197
US20200331973A1 (en) * 2017-09-01 2020-10-22 Lorven Biologics Private Limited Nucleic acid encoding crm197 and process for improved expression thereof
WO2019143911A1 (en) * 2018-01-19 2019-07-25 Obi Pharma, Inc. Crm197 protein expression
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
MY206212A (en) 2018-09-23 2024-12-04 Biological E Ltd Purified capsular polysaccharides of streptococcus pneumoniae
KR102142255B1 (ko) * 2019-12-05 2020-08-07 주식회사 제노포커스 Crm197 단백질 발현 방법
GB202108650D0 (en) * 2021-06-17 2021-08-04 Inst De Medicina Molecular Joaeo Lobo Antunes Production of cross-reactive material 197 fusion proteins
KR20230102682A (ko) * 2021-12-30 2023-07-07 (주)셀트리온 목적 단백질의 발현 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
DK2384765T3 (en) * 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
BR112012024898A2 (pt) * 2010-03-30 2015-10-06 Pfenex Inc expressão de nível elevado de proteínas recombinantes de toxinas
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
GB201209896D0 (en) 2012-06-01 2012-07-18 Fujifilm Diosynth Biotechnologies Uk Ltd Process
CN102766647A (zh) * 2012-07-25 2012-11-07 天津康希诺生物技术有限公司 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
ES2750525T3 (es) * 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
CN103266125A (zh) * 2013-06-04 2013-08-28 北京民海生物科技有限公司 白喉毒素突变体crm197的制备方法
WO2015134402A1 (en) 2014-03-03 2015-09-11 Scarab Genomics, Llc Enhanced production of recombinant crm197 in e. coli

Also Published As

Publication number Publication date
EA201791118A1 (ru) 2017-10-31
EP3221339B1 (en) 2024-08-21
US20170306302A1 (en) 2017-10-26
AU2015348922A8 (en) 2019-03-14
SA517381488B1 (ar) 2021-10-17
CA2968491A1 (en) 2016-05-26
EA035117B1 (ru) 2020-04-29
CA2968491C (en) 2023-09-26
BR112017010718A2 (pt) 2017-12-26
AU2015348922A1 (en) 2017-06-01
WO2016079755A1 (en) 2016-05-26
ZA201703150B (en) 2019-05-29
EP3221339C0 (en) 2024-08-21
CN107109416A (zh) 2017-08-29
AU2015348922B2 (en) 2020-01-23
US10280409B2 (en) 2019-05-07
EP3221339A1 (en) 2017-09-27
JP7042305B2 (ja) 2022-03-25
MX2017006506A (es) 2018-03-12
JP2017538444A (ja) 2017-12-28
JP2020171307A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
MX388191B (es) Polinucleótido optimizado por codones para la expresión de alto nivel de crm197.
TR201909037T4 (tr) Yeni protein deamidaz.
MX2016001555A (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
BR112017023646A2 (pt) proteínas agonistas de receptor de cd40 de cadeia simples
BR112016014405A2 (pt) cepa mutante atenuada de salmonela
BR112016006606A2 (pt) Molécula de ácido nucléico recombinante, molécula de aminoácido recombinante, construção de expressão recombinante, vetor recombinante, micro-organismo recombinante, composição, método de produção de aminoácidos, uso de uma molécula de ácido nucléico e processo de produção fermentativa
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
MX391716B (es) Promotor de catalasa modificado bidireccional de bacilo.
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX378585B (es) Sistema de expresion bacterial bicistronico
GEP20217307B (en) ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
BR112017003263A2 (pt) anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
IN2014MU01100A (es)
BR102014009838B8 (pt) Método para produzir um l-aminoácido
BR112016011095A2 (pt) Sequência de endolisina el188 modificada
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112017016194A2 (pt) método
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
MX2017007670A (es) Metodo de manufactura de proteina.
CN106029894A8 (zh) 使用具有过表达yajL基因的肠肝菌科细菌生产L‑氨基酸的方法